LAG3 and neoplasm: An early phase trial with metastatic breast cancer patients demonstrated the potency of this molecule in combination with paclitaxel, where 15 out of 30 women exhibited an objective tumour response.30 Thus, manipulating LAG-3 in patients with metastasis shows promise.